Abstract
Mast cell sarcoma is a rare disease characterized by localized, but destructive and rapid, growth of the tumor, high risk of distant metastasis, possibility of a leukemic phase, and poor prognosis. We report successful treatment of uterine mast cell sarcoma with imatinib in a 39-year-old woman who presented with abdominal distention and massive ascites. Routine treatment, such as combined chemotherapy, had little effect. We administered imatinib to the patient and achieved a good response in the absence of c-kit mutation, BCR/ABL, and FIP1L1–PDGFRα. Our results indicate that imatinib is of potential use in the treatment of mast cell sarcoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Horny HP, Parwaresch MR, Kaiserling E, et al. Mast cell sarcoma of the larynx. J Clin Pathol. 1986;39:596–602.
Kojima M, Nakamura S, Itoh H, et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol. 1999;12:739–43.
Guenther PP, Huebner A, Sobottka SB, et al. Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol. 2001;23:134–8.
Brcic L, Vuletic LB, Stepan J, et al. Mast-cell sarcoma of the tibia. J Clin Pathol. 2007;60(4):424–5.
Vega-Ruiz A, Cortes JE, Sever M, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33:1481–4.
Hirayama Y, Konuma Y, Kohda K, et al. Systemic mastocytosis without the typical mutation of codon 816 successfully treated with imatinib. Nippon Naika Gakkai Zasshi. 2008;97:2542–5.
Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol. 2003;27:1013–9.
Horny HP, Metcalfe DD, Bennett JM, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 54–63.
Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17.
Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25:571–6.
Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103:3222–5.
Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther. 2002;1:1115–24.
Hartmann K, Wardelmann E, Ma Y, et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology. 2005;129:1042–6.
Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717–25.
Hoffmann KM, Moser A, Lohse P, et al. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation. Blood. 2008;112:1655–7.
Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–32.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Ma, H.B., Xu, X., Liu, W.P. et al. Successful treatment of mast cell sarcoma of the uterus with imatinib. Int J Hematol 94, 491–494 (2011). https://doi.org/10.1007/s12185-011-0952-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-011-0952-2